Evofem Biosciences, Inc. EVFM
0.01 USD 0.00 (-1.64%)
Nov 4, 2026, 2:26 PM EST
0.006 Day range 0.0061
0.001 52-week range 0.014
- YTD
- -40.00%
- 1 year
- -45.45%
- Market cap
- 795.18K
- Revenue (ttm)
- 15.57M
- EPS (ttm)
- -0.11
- Shares out
- 85.46M
- Forward P/E
- -0.48
- YTD return
- -40.00%
- 1-year return
- -45.45%
- Volume
- 65.74K
- Avg volume
- 169.06K
- Open
- 0.0061
- Previous close
- 0.0061
- Day's range
- 0.006 – 0.0061
- 52-week range
- 0.001 – 0.014
- Beta
- -1.68
- Analysts
- Buy
- Price target
- 11.05 (+184066.7%)
2Y -0.0080 (-57.14%)
Key statistics
- Enterprise value
- 137.13M
- PEG ratio
- 0.00
- Price / sales
- 1.76
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 224.90%
- Free cash flow
- 68.23M
- Total cash
- 19.89M
- Total debt
- 125.74M
- Return on equity
- 0.00%
- Short % of float
- 24.67%
- 50-day average
- 0.74126
- 200-day average
- 3.61
Analyst view
Consensus: buy
Buy
Price target (mean) 11.05 +184066.7% upside
Now 0.006
- Target (low)
- 0.75
- Target (mean)
- 11.05
- Target (high)
- 45.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.44.
Financials — quick view
EVFM Revenue — quarterly 5.81M
EVFM Net income — quarterly -2.35M
EVFM EPS — quarterly -1.85
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.02 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.16 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | -0.44 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | 0.10 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -5.43 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jul 15, 2022 | Morgan Stanley | main | — | Underweight |
| Jun 2, 2022 | Laidlaw & Co. | init | — | Buy |
| May 25, 2022 | Piper Sandler | main | — | Overweight |
| May 11, 2022 | Morgan Stanley | main | — | Underweight |
| May 10, 2022 | Morgan Stanley | main | — | Underweight |
About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- evofem.com
News
Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy 
HUB Cyber Security Acquires Certain Senior Subordinated Convertible Notes And Purchase Rights Of Evofem Biosciences In Exchange Solely For HUB Equity Securities 
HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround 
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update 
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa 
Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS) 
Evofem Reports Fifth Consecutive Year of Net Sales Growth 
Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women's Health at Fierce JPM Week 2026 
Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store 
Financial Contrast: Evofem Biosciences (NASDAQ:EVFM) and BetterLife Pharma (OTCMKTS:PVOTF)
Your note
Sign in to keep a note on EVFM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRANS RUSSELL | Officer | Purchase | Jun 10, 2021 | 468,831 |
| CULWELL KELLY | Officer | Stock Award(Grant) | Feb 2, 2021 | 315,451 |
| FILE JUSTIN J | Chief Financial Officer | Stock Award(Grant) | Feb 17, 2022 | 810,982 |
| FITZPATRICK ALEXANDER A. | General Counsel | Stock Award(Grant) | Feb 17, 2022 | 516,422 |
| HALL WILLIAM WALMSLEY | Director | Purchase | Jun 14, 2020 | 5,000 |
| INVESCO, LTD. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 4, 2020 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Brothers Advisors, LLC | 3.13% | 2,583,616 | 826.50K | Jun 29, 2022 |
| Alyeska Investment Group, L.p. | 2.37% | 1,950,607 | 624.00K | Jun 29, 2022 |
| Vanguard Group, Inc. (The) | 1.58% | 1,304,514 | 417.31K | Jun 29, 2022 |
| Citigroup Inc. | 0.89% | 736,406 | 235.58K | Jun 29, 2022 |
| Blackrock Inc. | 0.28% | 234,225 | 74.93K | Jun 29, 2022 |
| Citadel Advisors Llc | 0.25% | 210,122 | 67.22K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.14% | 260,679 | 83.39K | Mar 30, 2022 |
| Vanguard Extended Market Index Fund | 0.08% | 154,404 | 49.39K | Mar 30, 2022 |
| Fidelity Extended Market Index Fund | 0.07% | 59,265 | 18.96K | Jun 29, 2022 |
| Fidelity Total Market Index Fund | 0.02% | 14,358 | 4.59K | Jun 29, 2022 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.01% | 8,791 | 2.81K | Jun 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.01% | 8,831 | 2.83K | Jun 29, 2022 |